The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)
Donepezil, 5 mg/d for 6 wk then 10 mg/d for 6 wk, and placebo daily for 12 wk in a double-blind cross-over paradigm, was added to the therapeutic regimen of 13 patients with schizophrenia or schizoaffective disorders, clinically stable on atypical antipsychotic medications. Patients had varying degrees of depressive symptoms, ranging from no depression to clinically significant depression. There was no worsening or induction of depression in individual patients or the group as a whole. In addition there was a statistically significant antidepressant effect in the group as a whole during the donepezil condition and a clinically significant antidepressant effect in the patients with clinically significant depressive symptoms, although there were not enough depressed patients in the group to conclude that donepezil may have antidepressant effects. Thus, in this study, donepezil did not induce or worsen depressive symptoms in schizophrenic and schizoaffective disorder patients.
Dartmouth Digital Commons Citation
Risch, S Craig; Horner, Michael D.; McGurk, Susan R.; Palecko, Simmy; Markowitz, John S.; Nahas, Ziad; and DeVane, C. Lindsay, "Donepezil Effects on Mood in Patients with Schizophrenia and Schizoaffective Disorder" (2005). Open Dartmouth: Peer-reviewed articles by Dartmouth faculty. 3852.